PharmaRoth Labs Statistics
Total Valuation
PharmaRoth Labs has a market cap or net worth of 391.
| Market Cap | 391 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaRoth Labs has 390.68 million shares outstanding.
| Current Share Class | 390.68M |
| Shares Outstanding | 390.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +8.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.24
| Current Ratio | 0.24 |
| Quick Ratio | 0.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -45.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 128.45% |
| Weighted Average Cost of Capital (WACC) | 2.65% |
| Revenue Per Employee | 100,075 |
| Profits Per Employee | -278,813 |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.83 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 43.46 |
| Average Volume (20 Days) | 135,722 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaRoth Labs had revenue of 200,150 and -557,626 in losses. Loss per share was -0.00.
| Revenue | 200,150 |
| Gross Profit | 80,478 |
| Operating Income | -379,290 |
| Pretax Income | -557,626 |
| Net Income | -557,626 |
| EBITDA | n/a |
| EBIT | -379,290 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 33 in cash and 250,000 in debt, with a net cash position of -249,967 or -0.00 per share.
| Cash & Cash Equivalents | 33 |
| Total Debt | 250,000 |
| Net Cash | -249,967 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -295,274 |
| Book Value Per Share | -0.00 |
| Working Capital | -295,274 |
Cash Flow
| Operating Cash Flow | -170,459 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 170,492 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 40.21%, with operating and profit margins of -189.50% and -278.60%.
| Gross Margin | 40.21% |
| Operating Margin | -189.50% |
| Pretax Margin | -278.60% |
| Profit Margin | -278.60% |
| EBITDA Margin | n/a |
| EBIT Margin | -189.50% |
| FCF Margin | n/a |
Dividends & Yields
PharmaRoth Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.44% |
| Shareholder Yield | -2.44% |
| Earnings Yield | -142,615.35% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 1, 2010. It was a forward split with a ratio of 5.
| Last Split Date | Jun 1, 2010 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
PharmaRoth Labs has an Altman Z-Score of -17.63 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.63 |
| Piotroski F-Score | 1 |